Nafoxidine possesses antitumor activity against an ascitic hepatoma.
Nafoxidine an antiestrogen is shown to possess antitumor activity against the Zajdela ascitic hepatoma. Nafoxidine prolonged the survival time of the rats injected with the tumor cells; complete regression of the tumor was observed when rats bearing a 3-day-old tumor were injected with this compound. Nafoxidine (Naf) also showed cytotoxic effects against the hepatoma cells in vitro. Naf competed with the binding of labelled estradiol to the tumor cells.
D000818:Animals; D001201:Ascites / Q000188:drug therapy; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004958:Estradiol / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D009256:Nafoxidine / Q000494:pharmacology / Q000627:therapeutic use*; D009368:Neoplasm Transplantation; D011759:Pyrrolidines / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains
D011759:Pyrrolidines; D009256:Nafoxidine; D004958:Estradiol